China Resources Pharmaceutical Group Ltd. (HK:3320)
:3320
Want to see HK:3320 full AI Analyst Report?
3320 Stock Chart & Stats
HK$4.61
HK$0.05(0.94%)
At close: 4:00 PM EST
HK$4.61
HK$0.05(0.94%)
Day’s Range― - ―
52-Week RangeHK$4.34 - HK$6.53
Previous CloseN/A
Volume6.08M
Average Volume (3M)13.76M
Market Cap
HK$29.65B
Enterprise ValueHK$103.60B
Total Cash (Recent Filing)HK$58.73B
Total Debt (Recent Filing)HK$104.87B
Price to Earnings (P/E)6.6
Beta0.77
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.95%
Share Statistics
EPS (TTM)N/A
Shares Outstanding6,282,510,300
10 Day Avg. Volume13,454,154
30 Day Avg. Volume13,759,791
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)0.49
Price to Sales (P/S)0.09
P/FCF Ratio1.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$6.74Price Target Upside46.20% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Cash Generation StrengthThe company generates persistently strong operating and free cash flow versus reported earnings, implying earnings quality and internal funding capacity. Over 2–6 months this durable cash-generation ability supports capex, working capital and distributions, and provides a buffer during cyclical pressure.
Integrated Pharma Business ModelA vertically integrated model spanning distribution, retail pharmacies and manufacturing creates diversified revenue streams and operational synergies. This structural positioning supports stable demand access, cross-selling and supply-chain control, reducing single-channel reliance and enhancing long-term resilience.
Steady Revenue Growth And Improving Gross MarginConsistent mid-single-digit revenue growth with recent gross-margin improvement indicates operational progress and market traction. These trends suggest sustainable top-line expansion and incremental margin recovery, which can steadily improve cash flow and business scalability over the medium term.
Bears Say
Rising LeverageMaterial increase in debt and a debt-to-equity near 1.8 elevates financial risk and reduces balance-sheet flexibility. Over 2–6 months this higher leverage raises refinancing and interest-rate vulnerability, potentially constraining strategic investments or dividend policies if earnings remain thin.
Very Thin Net MarginsNet margins at roughly one percent limit the company's ability to convert revenue growth into profits. Structurally low bottom-line margins increase sensitivity to cost inflation or pricing pressure and reduce retained earnings for reinvestment, hindering medium-term capital accumulation.
Weak Cash Cover Of Total DebtAlthough cash generation is strong relative to earnings, operating cash covers a small fraction of total debt, limiting rapid deleveraging. Over the medium term this structural mismatch constrains the pace of balance-sheet repair and raises risk if credit conditions tighten or refinancing costs rise.
China Resources Pharmaceutical Group Ltd. News
3320 FAQ
What was China Resources Pharmaceutical Group Ltd.’s price range in the past 12 months?
China Resources Pharmaceutical Group Ltd. lowest stock price was HK$4.34 and its highest was HK$6.53 in the past 12 months.
What is China Resources Pharmaceutical Group Ltd.’s market cap?
China Resources Pharmaceutical Group Ltd.’s market cap is HK$29.65B.
When is China Resources Pharmaceutical Group Ltd.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were China Resources Pharmaceutical Group Ltd.’s earnings last quarter?
Currently, no data Available
Is China Resources Pharmaceutical Group Ltd. overvalued?
According to Wall Street analysts China Resources Pharmaceutical Group Ltd.’s price is currently Undervalued.
Does China Resources Pharmaceutical Group Ltd. pay dividends?
China Resources Pharmaceutical Group Ltd. pays a Quarterly dividend of HK$0.139 which represents an annual dividend yield of 2.95%. See more information on China Resources Pharmaceutical Group Ltd. dividends here
What is China Resources Pharmaceutical Group Ltd.’s EPS estimate?
China Resources Pharmaceutical Group Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does China Resources Pharmaceutical Group Ltd. have?
China Resources Pharmaceutical Group Ltd. has 6,282,510,300 shares outstanding.
What happened to China Resources Pharmaceutical Group Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of China Resources Pharmaceutical Group Ltd.?
Currently, no hedge funds are holding shares in HK:3320
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
China Resources Pharmaceutical Group Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
HK$6.74 (46.20% Upside)
HK$6.74 (46.20% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Fundamentals
Return on Equity
7.98%
Trailing 12-Months
Asset Growth
2.12%
Trailing 12-Months
Company Description
China Resources Pharmaceutical Group Ltd.
China Resources Pharmaceutical Group Limited (CRPG) operates as an investment holding enterprise with core activities spanning the research, development, production, supply, and retail of pharmaceutical and healthcare products across Mainland China and Hong Kong. The company's diverse operations are organized into four primary divisions: Pharmaceutical Manufacturing, Pharmaceutical Distribution, Pharmaceutical Retail, and an 'Others' segment that includes property holding. CRPG's extensive product line features chemical drugs, traditional Chinese medicines, biopharmaceutical agents, and nutritional health items. These cater to a wide array of therapeutic areas, including cardiovascular and cerebrovascular conditions, metabolic and endocrine disorders, respiratory ailments, orthopedics, oncology, pediatric health, and anti-infection treatments, among others. Beyond manufacturing, the company delivers crucial supply chain services such as warehousing, logistics, and value-added solutions to drug producers, hospitals, distributors, and retail pharmacies. As of December 31, 2021, CRPG managed 801 retail pharmacies operating under the CR Care and Teck Soon Hong brands. Its products are also distributed to hospitals and other medical facilities. Founded in 2007 and based in Wan Chai, Hong Kong, the firm was formerly known as China Resources Medications Group Limited until its rebranding in December 2011. China Resources Pharmaceutical Group Limited is a subsidiary of CRH (Pharmaceutical) Limited.
3320 Stock 12 Month Forecast
Average Price Target
HK$6.74
▲(46.20% Upside)
Technical Analysis
China Medical System Holdings
―
Guangzhou Baiyunshan Pharmaceutical Holdings Company
―
Livzon Pharmaceutical Group
―
Shanghai Fosun Pharmaceutical (Group) Co
―
Grand Pharmaceutical Group Limited
―
Options Prices
Currently, No data available
---